The role of allelic expression imbalance (AER) in interindividual differences in CYP3A4 activity and it's clinical implications.
The role of allelic expression imbalance (AER) in interindividual differences in CYP3A4 activity and it's clinical implications.
批准号:
17390043
负责人:
IEIRI Ichiro
金额:
$9.64万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007
中文摘要
(1)开发常规的等位基因表达比(AER)检测试剂盒采用人CYP3A4基因88742位点的单核苷酸多态性(SNP), T/T-缺失作为标记,采用dna(即每个等位基因的纯合子)进行系列稀释标准样品进行校准,等位基因比例与荧光强度(VIC / FAM)之间的相关性非常好,我们使用TaqMan引物和探针集开发了CYP3A4基因AER常规检测试剂盒。使用该检测试剂盒,我们评估了日本健康志愿者个体AER与咪达唑仑和伊曲康唑代谢活性之间的关系。不幸的是,由于样本量小,没有观察到明确的关系。由于个体AER被成功估计,因此需要更大的样本量研究,使用更特异性的CYP3A4底物药物。(3)甲基化分析印迹控制中心(ICR)中存在多个CpG岛,ICR位于人类CYP3A4基因的上游。我们对位于82363 ~ 82893的4个CG位点进行分析,发现第14和第16个CG位点的甲基化频率与CYP3A4 m RNA表达水平呈显著负相关。(4)以CYP3A4基因5′-上游和3′-下游、5′-UTR和启动子区域的组蛋白乙酰化为靶点,各靶点的抗ac - h3结合能力存在较大的个体间差异,CYP3A4基因5′-上游的组蛋白乙酰化与mRNA表达显著相关。(5)上述4个CG位点的甲基化频率与CYP3A4基因上游约2000 bp的组蛋白乙酰化显著相关,提示ICR DNA甲基化参与了CYP3A4基因上游的组蛋白乙酰化,导致顺式作用现象,等位基因表达失衡。
英文摘要
(1) Development of conventional assay kit for the allelic expression ratio (AER) A single nucleotide polymorphism (SNP), T/T-deletion, position at 88742 in human CYP3A4 gene is used for the marker Serial dilution standard samples using DNAs (i e, homozygous for each allele) were used for the calibration Correlation between allelic ratio and fluorescence intensity (VIC / FAM) was excellent We developed conventional assay kit for AER in the CYP3A4 gene using TaqMan primers and probe sets.(2) Clinical Application Using this assay kit, we evaluated relationship between individual AER and metabolic activities of midazolam and itraconazole in Japanese healthy volunteers Unfortunately, due to the small sample sizes, clear relationships were not observed Since individual AER was estimated successfully, a larger sample size study using more specific substrate drugs for CYP3A4 is warranted.(3) Methylation analysis There are various CpG islands in the imprinting control center (ICR), ICR is located on the upstream of human CYP3A4 gene When we focused on 4 CG sites at position 82363 to 82893, methylation frequencies at 14th and 16th CG sites negatively correlated with the CYP3A4 m RNA expression levels at significantly.(4) Histone acetylation 5'-upstream and 3'-downstream regions, 5'-UTR, and promoter regions of the CYP3A4 gene were selected as targets Large interindividual differences in the anti-Ac-H3 binding capacity were observed in various target regions, histone acetylation in 5'-upstream regions of CYP3A4 was significantly correlated with mRNA expression.(5) Methylation status and Histone acetylation Methylation frequencies in above mentioned 4 CG sites were significantly correlated with histone acetylation at approximately 2000 bp upstream of the CYP3A4 gene These results suggest that DNA methylation in the ICR involved in the histone acetylation at the upstream of the CYP3A4 gene, leading to cis-acting phenomenon, allelic expression imbalance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Rifampin reduces the analgesic effect of transdermal fentanyl.
利福平降低透皮芬太尼的镇痛作用。
DOI:
--
发表时间:
2005
期刊:
The annals of Pharmacotherapy 39
影响因子:
--
作者:
[Takane, H., Nosaka, A., Wakushima, H., Hosokawa, K, Ieiri I et al.]
通讯作者:
Ieiri I et al.
Ieiri I : Epigenetic regulation of genes encoding drug-metabolizing enzymes and transporters ; DNA methylation and other mechanisms
Ieiri I:编码药物代谢酶和转运蛋白的基因的表观遗传调控;
DOI:
--
发表时间:
2008
期刊:
Curr Drug Metab 9
影响因子:
--
作者:
[Hirota, T., Takane, H., Higuchi, S]
通讯作者:
S
分子薬物動態学
分子药代动力学
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[Kayoko Ohura, Teruko Imai, 今井輝子, 今井輝子, 今井輝子, 今井 輝子, 今井輝子, 今井輝子, Teruko Imai, 今井輝子, 今井輝子]
通讯作者:
今井輝子
Ieiri I : Rifampin reduces the analgesic effect of transdermal fentanyl
Ieiri I :利福平降低透皮芬太尼的镇痛效果
DOI:
--
发表时间:
2005
期刊:
Ann Pharmacother 39
影响因子:
--
作者:
[Takane, H., Nosaka, A., Wakushima, H., Hosokawa, K]
通讯作者:
K
Pharmacogenetic determenants of variability in liped-lowering response to pravastat in therapy
治疗中普伐他降脂反应变异性的药物遗传学决定因素
DOI:
--
发表时间:
2006
期刊:
J Hum Genet 51
影响因子:
--
作者:
[Takane H, Miyata M, Burioka N, Shioemasa C, Shimizu E, Otsubo K, Ieiri I]
通讯作者:
Ieiri I
共 12 条
The role of miR-27a in regulation of P-gp expression
-
批准号:25670078
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2013
-
负责人:IEIRI Ichiro
-
依托单位:
Cohesin-dependentregulation of the expression of drug transporter genes
-
批准号:23659083
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2010
-
负责人:IEIRI Ichiro
-
依托单位:
Investigation of clinical impacts of CNV in the pharmacokinetic-related genes
-
批准号:20390048
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.4万
-
财政年份:2008
-
负责人:IEIRI Ichiro
-
依托单位:
In vivo functional characterization of the ABC transporters based on the genetic polymorphisms
-
批准号:13357020
-
项目类别:Grant-in-Aid for Scientific Research (A)
-
资助金额:$23.38万
-
财政年份:2001
-
负责人:IEIRI Ichiro
-
依托单位:
国内基金
海外基金
登录
查看更多内容
CYP3A5介导的索拉非尼肝细胞癌耐药及其DNA甲基化调控机制研究
-
批准号:LQ23H310003
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:汪佳琪
-
依托单位:
CYP3A5功能新解: 抑制肺腺癌侵袭转移及分子机制
-
批准号:81472702
-
项目类别:面上项目
-
资助金额:64.0万元
-
批准年份:2014
-
负责人:蒋峰
-
依托单位:
PBPK建模预测CYP3A5基因型对五酯胶囊和他克莫司药动相互作用的影响
-
批准号:81473409
-
项目类别:面上项目
-
资助金额:68.0万元
-
批准年份:2014
-
负责人:相小强
-
依托单位:
异基因造血干细胞移植患者CYP3A4、CYP3A5和MDR1基因多态性影响环孢素个体化用药的定量研究
-
批准号:81141039
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2011
-
负责人:姜德春
-
依托单位:
PCI术后患者CYP3A5和CYP2C19的基因多态性与氯吡格雷活性代谢物的血药浓度和抗血小板效果的相关性研究
-
批准号:30901830
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2009
-
负责人:邹建军
-
依托单位:
遗传、药物环境因素对白血病CYP3A5耐药机制的影响及逆转研究
-
批准号:30400183
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2004
-
负责人:王婷
-
依托单位:
CYP3A4和CYP3A5遗传变异对环孢霉素A代谢影响
-
批准号:30371668
-
项目类别:面上项目
-
资助金额:19.0万元
-
批准年份:2003
-
负责人:胡永芳
-
依托单位: